LUNG — Pulmonx Corporation

Summary of Pulmonx (LUNG) Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $21.5 million, a 5% increase year-over-year from $20.4 million.
• U.S. Revenue: $14 million, a modest 1% increase from $13.8 million in the prior year.
• International Revenue: $7.5 million, a 15% increase compared to $6.6 million last year.
• Gross Margin: Approximately 75%, up from 74% year-over-year.
• Operating Expenses: $30.4 million, a 4% increase from $29.2 million in Q3 2024.
• Net Loss: $14 million, or $0.34 per share, compared to a net loss of $14.1 million, or $0.36 per share, in the prior year.
• Cash Position: $76.5 million in cash and cash equivalents, down $7.7 million from Q2 2025.

2. Strategic Updates and Business Highlights

• Glen French has returned as CEO, with Derrick Sung as COO and CFO, both emphasizing a focus on value creation and operational efficiency.
• Pulmonx has established a market-leading position with its Zephyr Valves, which are recognized as the standard of care for severe emphysema.
• The company has a strong commercial infrastructure with a significant global sales force and established reimbursement pathways in the U.S. and other markets.
• Plans to improve execution and align spending with growth expectations, focusing on profitable growth and extending cash runway.

3. Forward Guidance and Outlook

• Full Year 2025 Revenue Guidance: Revised to $89 million to $90 million.
• Gross Margin Guidance: Expected to be approximately 73% for the full year.
• Operating Expense Guidance: Projected to be between $125 million and $126 million, including about $21 million in noncash stock-based compensation.

4. Challenges and Points of Concern

• U.S. Growth Deceleration: Sales growth in the U.S. has slowed, raising concerns about the effectiveness of recent investments.
• Operating Leverage Issues: The company has struggled to achieve operating leverage, impacting profitability.
• Cash Utilization: Total cash utilization for the first three quarters of 2025 was approximately $25 million, necessitating a focus on extending the cash runway.
• Underperforming Territories: There are disparities in performance across different regions, with some areas not meeting growth expectations.

5. Notable Q&A Insights

• Management acknowledged the complexity of the patient referral process and emphasized the need for efficiency in moving patients through treatment.
• Glen French indicated that while there is optimism about improving underperforming territories, specific details on strategies will be provided in future calls.
• Derrick Sung clarified that extending the cash runway involves reallocating expenses to more productive areas rather than seeking external financing.
• Both executives highlighted the importance of focusing on high-impact initiatives and avoiding speculation on future strategies until they have more data.

Overall, Pulmonx is navigating a challenging environment with a focus on improving execution and profitability while addressing growth concerns, particularly in the U.S. market.